# P29678.A01

# **Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of the claims in the application:

# **Listing of Claims:**

1. - 76. (cancelled)


77. (new) A pharmaceutical or cosmetic composition comprising at least one of a pharmaceutically or cosmetically acceptable carrier and a pharmaceutically or cosmetically acceptable adjuvant and at least one active ingredient selected from compounds of formulae D1 to D14, including tautomers, stereoisomers thereof, pharmaceutically acceptable salts, salt derivatives, tautomers and stereoisomers thereof:

- all substituted and unsubstituted, condensed and non-condensed homocyclic and heterocyclic basic structures having more than six members in ring (a) as well as having less than five members in ring (b) are represented;
- basic structures may contain double bonds;

## P29678.A01

- Y represents O, S or NR4;
- R2 symbolizes a substitution of cyclic basic structure in (a) and represents one or several substituents;
- R1 to R6 are identical or different and are selected from hydrogen, unsubstituted or substituted, straight chain or branched C<sub>1</sub>- to C<sub>12</sub> alkyl, C<sub>2</sub>- to C<sub>12</sub> alkenyl and C<sub>2</sub>- to C<sub>12</sub> alkynyl, hydroxy, thiol, C<sub>1</sub>- to C<sub>12</sub> alkoxy, C<sub>1</sub>- to C<sub>12</sub> alkylthio, unsubstituted or substituted, uncondensed or condensed aryl and cycloalkyl optionally containing one or several heteroatoms selected from N, O, P and S, unsubstituted or substituted amino, unsubstituted or substituted carbonyl, unsubstituted or substituted thiocarbonyl and unsubstituted or substituted imino; and
- heteroaromatic or heterocyclic radicals are bound to a basic structure of formula D1 via a C atom or a heteroatom;

- Y1 and Y2 are identical or different and represent O. S or NR3:
- R1 to R4 are identical or different and are selected from hydrogen, unsubstituted or substituted, straight chain or branched C<sub>1</sub>- to C<sub>12</sub> alkyl, C<sub>2</sub>- to C<sub>12</sub> alkenyl and C<sub>2</sub>- to C<sub>12</sub> alkynyl, hydroxy, thiol, C<sub>1</sub>- to C<sub>12</sub> alkoxy, C<sub>1</sub>- to C<sub>12</sub> alkylthio, unsubstituted or substituted, uncondensed or condensed aryl and cycloalkyl optionally containing one or several heteroatoms selected from N, O, P and S, unsubstituted or substituted amino, unsubstituted or substituted carbonyl, unsubstituted or substituted thiocarbonyl and unsubstituted or substituted imino; and
- heteroaromatic or heterocyclic radicals are bound to a basic structure of formula D2 via a C atom or a heteroatom;



- X and Z independently represent CH, CR3 or N;
- partial rings may be substituted or unsubstituted, condensed or noncondensed and may contain zero to three double bonds and zero to four heteroatoms and heteroatom-containing groups as defined for X and Z;
- R1 to R4 are identical or different and are selected from hydrogen, unsubstituted or substituted, straight chain or branched C<sub>1</sub>- to C<sub>12</sub> alkyl, C<sub>2</sub>- to C<sub>12</sub> alkenyl and C<sub>2</sub>- to C<sub>12</sub> alkynyl, hydroxy, thiol, C<sub>1</sub>- to C<sub>12</sub> alkoxy, C<sub>1</sub>- to C<sub>12</sub> alkylthio, unsubstituted or substituted, uncondensed or condensed aryl and cycloalkyl optionally containing one or several heteroatoms selected from N, O, P and S, unsubstituted or substituted amino, unsubstituted or substituted carbonyl, unsubstituted or substituted thiocarbonyl and unsubstituted or substituted imino; and
- heteroaromatic or heterocyclic radicals are bound to a basic structure of formula D3 via a C atom or a heteroatom;
- ring systems of basic structures may contain zero to three double bonds;

R11-R12 D4

# wherein

 R11 and R12 represent heterocyclic systems having three to eight ring members, which may be connected to each other directly via heteroatoms, via carbon atoms or a heteroatom or carbon atom;  partial rings indicated by R1 and R2 may be substituted or unsubstituted, condensed or noncondensed and may contain zero to three double bonds and further heteroatoms and hetero atom-containing groups;

#### wherein

- X represents O, S, NH or NR2;
- radicals R1 symbolize the substitution of a basic six-membered ring structure;
- a basic heterocyclic structure may possess zero to three double bonds and up to three further heteroatoms as defined for X;
- R1 and R2 are selected from hydrogen, unsubstituted or substituted, straight chain or branched C<sub>1</sub>- to C<sub>12</sub> alkyl, C<sub>2</sub>- to C<sub>12</sub> alkenyl and C<sub>2</sub>- to C<sub>12</sub> alkynyl, hydroxy, thiol, C<sub>1</sub>- to C<sub>12</sub> alkoxy, C<sub>1</sub>- to C<sub>12</sub> alkylthio, unsubstituted or substituted, uncondensed or condensed aryl and cycloalkyl optionally containing one or several heteroatoms selected from N, O, P and S, unsubstituted or substituted amino, unsubstituted or substituted carbonyl, unsubstituted or substituted thiocarbonyl and unsubstituted or substituted imino;
- heteroaromatic or heterocyclic radicals are bound to a basic structure of formula D5 via a C atom or a heteroatom;

#### wherein


X represents O, S, NH or NR9;

- a basic five-membered ring structure may additionally contain up to three further heteroatoms as defined for X, which may be identical or different;
- a basic five-membered ring structure may contain zero to two double bonds;
- R1 to R9 are selected from hydrogen, unsubstituted or substituted, straight chain or branched C<sub>1</sub>- to C<sub>12</sub> alkyl, C<sub>2</sub>- to C<sub>12</sub> alkenyl and C<sub>2</sub>- to C<sub>12</sub> alkynyl, hydroxy, thiol, C<sub>1</sub>- to C<sub>12</sub> alkoxy, C<sub>1</sub>- to C<sub>12</sub> alkylthio, unsubstituted or substituted, uncondensed or condensed aryl and cycloalkyl optionally containing one or several heteroatoms selected from N, O, P and S, unsubstituted or substituted amino, unsubstituted or substituted carbonyl, unsubstituted or substituted thiocarbonyl and unsubstituted or substituted imino; and
- heteroaromatic or heterocyclic radicals are bound to a basic structure of formula D6 via a C atom or a heteroatom;

- Y1 and Y2 are identical or different and represent O, S, NH or NR4;
- aromatic systems of basic structures may contain up to four substituents,
   which may be identical or different;
- R1 to R4 are selected from hydrogen, unsubstituted or substituted, straight chain or branched C<sub>1</sub>- to C<sub>12</sub> alkyl, C<sub>2</sub>- to C<sub>12</sub> alkenyl and C<sub>2</sub>- to C<sub>12</sub> alkynyl, hydroxy, thiol, C<sub>1</sub>- to C<sub>12</sub> alkoxy, C<sub>1</sub>- to C<sub>12</sub> alkylthio, unsubstituted or substituted, uncondensed or condensed aryl and cycloalkyl optionally containing one or several heteroatoms selected from N, O, P and S,

unsubstituted or substituted amino, unsubstituted or substituted carbonyl, unsubstituted or substituted thiocarbonyl and unsubstituted or substituted imino; and

- heteroaromatic or heterocyclic radicals are bound to a basic structure of formula D7 via a C atom or a heteroatom;
- R2 and R3 symbolize a substitution of respective ring systems and represent one to four radicals;



- X and Z are identical or different and are independently selected from hydroxy, thiol, C<sub>1</sub>- to C<sub>12</sub> alkoxy, C<sub>1</sub>- to C<sub>12</sub> alkylthio, unsubstituted or substituted, uncondensed or condensed aryl and cycloalkyl optionally containing one or several heteroatoms selected from N, O, P and S, and amino (NH2, NHR1, NR1R2);
- Y represents O, S or NR3;
- R1, R2 and R3 are identical or different and are selected from hydrogen, unsubstituted or substituted, straight chain or branched C<sub>1</sub>- to C<sub>12</sub> alkyl, C<sub>2</sub>- to C<sub>12</sub> alkenyl and C<sub>2</sub>- to C<sub>12</sub> alkynyl, hydroxy, thiol, C<sub>1</sub>- to C<sub>12</sub> alkoxy, C<sub>1</sub>- to C<sub>12</sub> alkylthio, unsubstituted or substituted, uncondensed or condensed aryl and cycloalkyl optionally containing one or several heteroatoms selected from N, O, P and S, unsubstituted or substituted amino, unsubstituted or substituted carbonyl, unsubstituted or substituted thiocarbonyl and unsubstituted or substituted imino; and
- heteroaromatic or heterocyclic radicals are bound to a basic structure of formula D8 via a C atom or a heteroatom;

- Z represents S or P;
- Y1 and Y2 represent O, S, NH, NR4 or NR5;
- R1 to R5 are selected from hydrogen, unsubstituted or substituted, straight chain or branched C<sub>1</sub>- to C<sub>12</sub> alkyl, C<sub>2</sub>- to C<sub>12</sub> alkenyl and C<sub>2</sub>- to C<sub>12</sub> alkynyl, hydroxy, thiol, C<sub>1</sub>- to C<sub>12</sub> alkoxy, C<sub>1</sub>- to C<sub>12</sub> alkylthio, unsubstituted or substituted, uncondensed or condensed aryl and cycloalkyl optionally containing one or several hetero atoms selected from N, O, P and S, unsubstituted or substituted amino, unsubstituted or substituted carbonyl, unsubstituted or substituted thiocarbonyl and unsubstituted or substituted imino;
- heteroaromatic or heterocyclic radicals are bound to a basic structure of formula D9 via a C atom or a hetero atom;

## wherein

• R1, R2, R3 and R4 are selected from hydrogen, unsubstituted or substituted, straight chain or branched C<sub>1</sub>- to C<sub>12</sub> alkyl, C<sub>2</sub>- to C<sub>12</sub> alkenyl and C<sub>2</sub>- to C<sub>12</sub> alkynyl, hydroxy, thiol, C<sub>1</sub>- to C<sub>12</sub> alkoxy, C<sub>1</sub>- to C<sub>12</sub> alkylthio, unsubstituted or substituted, uncondensed or condensed aryl and cycloalkyl optionally containing one or several heteroatoms selected from N, O, P and S, unsubstituted or substituted amino, unsubstituted or substituted carbonyl,

unsubstituted or substituted thiocarbonyl and unsubstituted or substituted imino;

 heteroaromatic or heterocyclic radicals are bound to a basic structure of formula D10 via a C atom or a heteroatom;

## wherein

- R1, R2 and R3 are selected from hydrogen, unsubstituted or substituted, straight chain or branched C<sub>1</sub>- to C<sub>12</sub> alkyl, C<sub>2</sub>- to C<sub>12</sub> alkenyl and C<sub>2</sub>- to C<sub>12</sub> alkynyl, hydroxy, thiol, C<sub>1</sub>- to C<sub>12</sub> alkoxy, C<sub>1</sub>- to C<sub>12</sub> alkylthio, unsubstituted or substituted, uncondensed or condensed aryl and cycloalkyl optionally containing one or several heteroatoms selected from N, O, P and S, unsubstituted or substituted amino, unsubstituted or substituted carbonyl, unsubstituted or substituted thiocarbonyl and unsubstituted or substituted imino;
- heteroaromatic or heterocyclic radicals are bound to a basic structure of formula D11 via a C atom or a hetero atom;

- X and Z are identically or different and are independently selected from hydroxy, thiol, C<sub>1</sub>- to C<sub>12</sub> alkoxy, C<sub>1</sub>- bis C<sub>12</sub>-alkylthio, unsubstituted or substituted, uncondensed or condensed aryl and cycloalkyl optionally containing one or several heteroatoms selected from N, O, P and S, and amino (NH2, NHR2, NR2R3);
- Y represents O, S or NR4;

- R1, R2, R3 and R4 are identical or different and are selected from hydrogen, unsubstituted or substituted, straight chain or branched C<sub>1</sub>- to C<sub>12</sub> alkyl, C<sub>2</sub>- to C<sub>12</sub> alkenyl and C<sub>2</sub>- to C<sub>12</sub> alkynyl, hydroxy, thiol, C<sub>1</sub>- to C<sub>12</sub> alkoxy, C<sub>1</sub>- to C<sub>12</sub>-alkylthio unsubstituted or substituted, uncondensed or condensed aryl and cycloalkyl optionally containing one or several heteroatoms selected from N, O, P and S, unsubstituted or substituted amino, unsubstituted or substituted carbonyl, unsubstituted or substituted thiocarbonyl and unsubstituted or substituted imino;
- heteroaromatic or heterocyclic radicals are bound to a basic structure of formula D12 via a C atom or a heteroatom;

- X and Z are identical or different and are independently selected from hydroxy, thiol, C<sub>1</sub>- to C<sub>12</sub> alkoxy, C<sub>1</sub>- to C<sub>12</sub> alkylthio, unsubstituted or substituted, uncondensed or condensed aryl and cycloalkyl optionally containing one or several heteroatoms selected from N, O, P and S, and amino (NH2, NHR2, NR2R3);
- Y represents O, S or NR5;
- an aromatic system may be a six-membered ring including a homo- or heteroaromatic system having one to four N atoms in a ring;
- R1 symbolizes a substitution of an aromatic radical of a basic structure and may represent up to five substituents;
- R1, R2, R3 and R4 are identical or different and are selected from hydrogen, unsubstituted or substituted, straight chain or branched C<sub>1</sub>- to C<sub>12</sub> alkyl, C<sub>2</sub>- to C<sub>12</sub> alkenyl and C<sub>2</sub>- to C<sub>12</sub> alkynyl, hydroxy, thiol, C<sub>1</sub>- to C<sub>12</sub> alkoxy, C<sub>1</sub>- to C<sub>12</sub> alkylthio, unsubstituted or substituted, uncondensed or

condensed aryl and cycloalkyl optionally containing one or several heteroatoms selected from N, O, P and S, unsubstituted or substituted amino, unsubstituted or substituted carbonyl, unsubstituted or substituted thiocarbonyl and unsubstituted or substituted imino;

 heteroaromatic or heterocyclic radicals are bound to a basic structure of formula D13 via a C atom or a heteroatom;

- Y represents O, S or NR5;
- R1, R2, R3 and R4 are identical or different and are selected from hydrogen, unsubstituted or substituted, straight chain or branched C<sub>1</sub>- to C<sub>12</sub> alkyl, C<sub>2</sub>- to C<sub>12</sub> alkenyl and C<sub>2</sub>- to C<sub>12</sub> alkynyl, hydroxy, thiol, C<sub>1</sub>- to C<sub>12</sub> alkoxy, C<sub>1</sub>- to C<sub>12</sub> alkylthio, unsubstituted or substituted, uncondensed or condensed aryl and cycloalkyl optionally containing one or several heteroatoms selected from N, O, P and S, unsubstituted or substituted amino, unsubstituted or substituted carbonyl, unsubstituted or substituted thiocarbonyl and unsubstituted or substituted imino; and
- heteroaromatic or heterocyclic radicals are bound to a basic structure of formula D14 via a C atom or a heteroatom.

# P29678.A01

78. (new) The composition of claim 77, wherein the composition comprises at least one active ingredient selected from compounds of the following formulae, including tautomers, stereoisomers thereof, pharmaceutically acceptable salts, salt derivatives, tautomers and stereoisomers thereof:

D1.001	Me O Me H H N NMe <sub>2</sub>
D1.002	S HN O N N
D1.003	

D1.004	S S
	H <sub>3</sub> C O

D2.001	H <sub>3</sub> C N N NH <sub>2</sub> O Br
D2.003	Me NH <sub>2</sub>
D2.004	S N F  N-N  O  N-N  O  CI

D2.005	
D2.006	EtO O NH <sub>2</sub> O OEt
D2.007	N O OEt
D2.008	N-N CI

D3.002	H <sub>3</sub> C NH
D3.003	N N N N N N N N N N N N N N N N N N N
D3.004	O N CI
D3.005	H <sub>3</sub> C CH <sub>3</sub> NH  CH <sub>3</sub> C CH <sub>3</sub>
D3.006	N. N

D3.007	Br
	S N S
D3.008	
D3.009	
D3.010	
D3.011	
D3.012	

D3.013	
	S N O
	N N N
	<u> </u>
D3.014	O=N
	N-\
	O_N;
D3.015	N-N N-N
	} <u></u> Br
D3.016	Br
	N N Br
D3.017	O <sub>1</sub>
	N N O
D3.018	0—\_N
	N S O N O

D3.019	S N O
D3.020	
D3.021	O-N-N-N-N-N-N-N-N-N-N-N-N-N-N-N-N-N-N-N
D3.022	H <sub>3</sub> C N N N N N N N CI
D3.023	
D3.024	

D3.025	H <sub>3</sub> C O HN
	ОН
D3.026	N Q
D3.027	
D3.029	

D3.030	0,
	N N
	n n
D3.031	
	O-N-
	,
D3.032	
	8 🗸
D3.033	. //
	N O N
	O N
D3.034	,
D3.034	
	0,
	N 
D3.035	
	N N
	N
	<b>≡ Z</b>

D3.037	H <sub>3</sub> C N N N CH <sub>3</sub>
D3.038	N O F F F F F F F F F F F F F F F F F F
D3.039	
D3.040	H <sub>3</sub> C O O N CH <sub>3</sub>
D3.042	N S

D3.043	S N F
D3.044	
D3.045	
D3.046	
D3.047	
D3.048	

D3.049	N o F F
	S F F
D3.050	N S N N N N N N N N N N N N N N N N N N
D3.051	
D3.052	
D3.054	H <sub>3</sub> C N N CH <sub>3</sub>
D3.055	O N CI CI CI

D0.050	N.
D3.056	NH.//
	H
D3.057	NN
D3.058	OHN OH OH
D3.059	
D3.060	
D3.061	S S O N
D3.062	H. H.

D3.063	O V
	N N
	o, PN
D3.064	
	N N N
	O N
D3.066	
D3.000	N-N-0-
D3.067	
	<b>S</b>
	O S O
D3.069	O <sub>I</sub>
	0000
	-N
	0 <sup>-N</sup> ,0
D3.070	∧ ~ N
	6-4-7-1
	0

D3.072	O N N
D3.073	
D3.074	
	N-C
D3.077	0
	N Q
D3.078	
D3.079	0. N. 0.
D3.080	N Q F F
	S F F

D3.081	
D3.082	O CI
D3.083	
D3.084	
D3.086	H <sub>3</sub> C HN F CH <sub>3</sub>

D2 007	
D3.087	
D3.088	
D3.089	O N N N OH OH
D3.091	O N N N N C I
D3.092	S F F
D3.093	CI N S

D3.094	S TO S
Do 005	N N
D3.095	
D3.096	N O O O
D3.097	O=N+ ON-N-N-N-N-N-N-N-N-N-N-N-N-N-N-N-N-N-N-
D3.098	
D3.099	

D3.100	
D3.101	CI N N N N
D3.102	O N S O
D3.103	
D3.104	
D3.105	

D3.106	
D3.107	
D3.108	
D3.109	O N-O
D3.110	

D3.111	
	N N N N N N N N N N N N N N N N N N N
	0_
D3.112	CI N-O O
	N O N O
D3.113	<u> </u>
	0 \_N
	N N N
	Ś
	l Br
D3.114	
	N N N
	o" `s' <sup>N</sup>

D3.116	
D3.117	
D3.118	NH <sub>2</sub> N S O S N NH <sub>2</sub>
D3.119	

D3.120	CI NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
--------	--

D4.001	H <sub>3</sub> C N N N N N N N N N N N N N N N N N N N
D4.002	H <sub>3</sub> C NH
D4.003	
D4.004	o s o s

D4.005	0, ^-
D4.005	S S S S S S S S S S S S S S S S S S S
D4.000	
D4.006	
D4.007	
D4.008	N.N.N.N.N.N.N.N.N.N.N.N.N.N.N.N.N.N.N.
D4.009	N N N N N N N N N N N N N N N N N N N
D4.010	

D4.011	0,
54.011	
	0
	ĊI
D4.012	
	<u> </u>
	_N >=0
	N N
	~
D4.013	
	N N
	N N N N
	0-N
D4.014	
	, , , , , , , , , , , , , , , , , , ,
	o s n n
	Ś
	N O
	Ó
D4.015	0 × s
	N N
	\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \
D4.016	o <sub>≈N</sub> +o⁻
	\ <u>\</u>

D4.017	
D4.018	
D4.019	
D4.020	
D4.021	

D4.022	ÇI
D4.022	
	0-N-N-N-N-N-N-N-N-N-N-N-N-N-N-N-N-N-N-N
D4.023	N-O
D4.024	
	H <sub>3</sub> C CH <sub>3</sub>
	O N N N N
	N N N
D4.025	O N
:	ON NO NEO
	/
D4.026	
	N-N-N-N-N
	F

D4.027	\.
	N-
	N
	ő
D4.028	O <sub>N</sub> + O −
D4.030	,0
D4.030	0 N-(
D4.031	/
	°/
	N
	0= N
	°°
D4.032	NI—NI O
D4.032	

D4.034	
54.004	
D4.035	0
	N N N N N N N N N N N N N N N N N N N
D4.036	
D4.037	
D4.038	H <sub>3</sub> C N CH <sub>3</sub>
	HN H
	CI

D4.039	
	NH
,	
D4.040	
	N-N N-N
D4.041	ş
	N CI
	CH <sub>3</sub>
	OH <sub>3</sub>
D4.042	
	° N
	N N N N
	ONN
	1
D4.044	0
	N
	N N N N N N N N N N N N N N N N N N N
	N N N O
	1

D4.045	
D4.046	
D4.047	S O CI
D4.048	
D4.049	H <sub>3</sub> C H <sub>3</sub> C N O O S

D4.050	N S N N N N N N N N N N N N N N N N N N
D4.051	O N N N N N N N N N N N N N N N N N N N
D4.052	
D4.053	N N N
D4.054	

D4.055	
D4.056	O O O O O O O O O O O O O O O O O O O
D4.057	
D4.058	H <sub>3</sub> C NH
D4.059	CI

D4.060	
D4.061	S O O
D4.062	
D4.063	
D4.064	

D4.065	
D4.066	
D4.067	
D4.068	
D4.069	

D4.070	
	N O N=O
D4.071	
D4.072	
D4.073	
D4.074	ON ON ON
D4.075	CI CI CI O

D4.076	
D4.077	
D4.078	
D4.079	

D4.080	N III
	Br—O
	<b>"</b>
D4.081	
	CI
	0-1
D4.082	
	o,
	N s
	N N
D4.083	<u> </u>
	CI—CI—O
	N N N N N N N N N N N N N N N N N N N
D4.084	
	N. N.
D4.085	
	N

D4.086	S O
D4.087	N CI CI
D4.088	ONTO
D4.089	
D4.090	0.N-0- N-N-N-N-0
D4.091	CI N S
D4.092	

D4.093	N O O O
D4.095	
D4.096	>-N
D4.098	Br O
D4.099	O N S O
D4.100	S O N O F

D4.101	
D4.102	
D4.103	
D4.104	$H_3C$ $N$
D4.105	

D4 400	
D4.106	
D4.107	
D4.110	
D4.111	CI NO O
D4.112	CI O'S'O
D4.113	

D4.114	N O
	CI
D4.115	
D4.116	
D4.117	

D4.118	

D5.001	H <sub>3</sub> C NH NH <sub>3</sub> C O
D5.002	H <sub>3</sub> C N N N N N N
D5.003	
D5.004	

D5.005	H <sub>3</sub> C CH <sub>3</sub>
	ŅH
	H <sub>3</sub> C O
	H <sub>3</sub> C O
D5.006	° s
	CI
	CI
D5.007	
	N
	ĊI
D5.008	
	o >/
	N N
	S

D5.009	0 0
	\rightarrow   \qua
	0-10-0
D5.010	0, 0
20.010	s s
D5.011	/ 0×
D5.013	_ 0 ~ \
	o N T N O
D5.014	
D5.014	O
	0 0 0 0
D5 045	
D5.015	, o
	0 N
	Ö

D5.016	,
	·
	N O
	>0
	N-
	N N
	<u>-</u> o'
D5.017	N—N 0
	N. 11 1
DE 049	
D5.018	0
	N O NO
D5.019	0>
	ő
	N ONEO

D5.020	
	H <sub>3</sub> C CH <sub>3</sub>
D5.021	CF.
D5.022	S CI CI CH <sub>3</sub>
D5.023	
D5.024	

D5.025	S N F  N-N  O  N-N  O  CI
D5.026	
D5.027	S O N CI
D5.028	
D5.029	H <sub>3</sub> C H <sub>3</sub> C N O O S

D5.030	
55.000	O N N N N N N N N N N N N N N N N N N N
D5.031	
D5.032	O O O O
D5.033	
D5.034	H <sub>3</sub> C NH

D5.005	
D5.035	
D5.036	
D5.037	ON ONO
D5.038	
D5.039	

D5.040	N N N N N N N N N N N N N N N N N N N
D5.041	O O O O O O O O O O O O O O O O O O O
D5.042	CI CI CI O
D5.043	N N N N N N N N N N N N N N N N N N N
D5.044	

D5.045	O N
1	No Nio
	O N
D5.046	o F s o
D5.047	O N O
D5.048	
D5.050	O N O F
D5.051	

D5.052	
D5.053	

D6.001	H <sub>3</sub> C NH NH NH <sub>3</sub> C O
D6.002	H <sub>3</sub> C NH NH NH ON NH

D6.003	
D6.004	
D6.006	O N N N N CI
D6.007	H S S
D6.008	N N N N N N N N N N N N N N N N N N N

D6.009	
D6.010	
D6.011	
D6.012	
D6.013	N N N N

D6.014	0 0
	0 <sub>N</sub> +0
	0
D6.015	
	N. T
	N—N
	0 N
D6.016	H <sub>3</sub> C
	N <sub>N</sub> S
	NH <sub>2</sub>
	Br
D6.017	0—\_N \_
	S O O N+.O
	o o
D0 040	
D6.018	N O
D0 040	
D6.019	
	, <u>}</u>
	N N
	N N N
	"T"

D6.020	0=S=0
D6.021	ON N Br
D6.022	N.N.
D6.023	
D6.024	
D6.025	

De 026	. 0 0
D6.026	O P P P P P P P P P P P P P P P P P P P
D6.027	
D6.028	H <sub>3</sub> C N CH <sub>3</sub>
D6.029	
D6.030	

D6.031	
D6.032	N-N-N-N-N
D6.033	
D6.034	O N F F F
D6.035	
D6.036	ON ON N

D6.037	
	N N
	, s , s
	000
D6.038	N N N O
	O N
D6 020	<u> </u>
D6.039	s s
	N N Br
D6.040	`0
	N >O
	~
D6.041	

D6.042	, N
D6.043	O N N N N N CI
D6.044	
D6.045	N-N N
D6.046	
D6.047	N O F F F F F F F F F F F F F F F F F F

D6.048	
D6.049	S-N N CI
D6.050	Me N NH <sub>2</sub>
D6.051	
D6.052	
D6.053	S N O

D6.054	
D6.055	
D6.056	H <sub>3</sub> C H <sub>3</sub> C N O N O S
D6.057	N S N N
D6.058	N O F F F F F F F F F F F F F F F F F F
D6.059	N S N S N S N S N S N S N S N S N S N S

D6.060	0 N N
	N $N$ $N$
	F O
D6.061	
	CI
D6.062	H <sub>3</sub> C O N O N O N O N O N O N O N O N O N O
D6.063	H <sub>3</sub> C N N NH
	H <sub>3</sub> C O CI

D6.064	
	$N = NH_2$ $NH_2$
D6.065	O CI
D6.066	
D6.067	
D6.068	

D6.069	H <sub>3</sub> C NH
	N N N
	N
D6.070	Ĭ,
	CI—N.
DC 074	
D6.071	, cı
	0 N Y O
	CI
D6.072	
D0.072	
	S S
D0 070	s o
D6.073	S O O
D6.074	0, ~
	N-N N=0

D6.075	
D6.076	
D6.077	
D6.078	N N N N N N N N N N N N N N N N N N N
D6.079	F N N O O

D6.080	+
	N N N CI
D6.081	
D6.082	\( \)
	CI
D6.083	N O F F F F F F F F F F F F F F F F F F
D6.084	N N O
D6.085	SN

D6.086	N-N
	o o
D6.087	
D6.088	
	F P
	N N
	N N N
D6.089	
	Br—C
D6.090	

D6.091	<u></u>
	0, N-
D6.092	
	CI
	o No
	0
D6.094	
	o, \$=\frac{\frac{1}{2}}{2}
	N s
	S N
D6.095	Ŋ
	CI
	/ 0
D6.096	O N N OH
	N H OH
	CI
D6.097	
	N.N.N.N.N.N.N.N.N.N.N.N.N.N.N.N.N.N.N.

D6.098	O-CI
D6.099	Br O N
D6.100	
D6.101	N CI CI
D6.102	
D6.103	N N F F F F

D6.105	0 ==
Do: 100	O.N.O
	N-N-N-N-O
	\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \
50.400	
D6.106	O O
	O N O
	N S O
D6.107	
	N-\ N-\ O-\
	S O Br
	Br <sup>'</sup>
D6.108	0
	N
	Br O N
	N=O O
50.440	, and the second
D6.110	
	N N
	°
	S

D6.111	N
	N O O O O O O O O O O O O O O O O O O O
D6.112	O N N N N N N N N N N N N N N N N N N N
D6.113	
D6.114	
D6.115	Br O
D6.116	

D6.117	
D0.117	
D6.118	
D6.119	S N S Br
D6.120	
D6.121	0,50
D6.122	Oolo
D6.123	

D6.124	,
D0.124	
	N S
	) s'
	s N
D0 405	, ,
D6.125	
	N N N N N N N N N N N N N N N N N N N
	N N=N
D6.126	
D0.120	
	\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \
	N N
	T N N
	\$ \$
	↓ H
	0_
D6.127	0
30.127	0 N <sup>+</sup> -o <sup>-</sup>
	N N
	Br N N
	N'N'N'N
	Ñ-₀' .
D6.129	9 N-
	N. N.
	N-()

D6.130	Q
	s
D6.131	
D0.131	D <sub>N</sub> o
	N O
	<b>\$</b> 0
	CI
D6.132	NH <sub>2</sub>
	N S
	0 0 5 0
	S N
D6.133	NH <sub>2</sub>
50.100	N.
D6 124	
D6.134	
	N
	N

s	D6.135	S-N N S
---	--------	---------

D7.001	O <sub>2</sub> N
D7.003	~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~

D8.003	$\begin{array}{c c}  & & & \\  & & & &$
D8.004	NH S
D8.005	N-N N N Br
D8.006	
D8.007	

D8.008	
	_ 00
	, N
	>=0
	n (
	F
D8.009	
B0.003	
	9 N
	S N
	N N
D8.010	
D6.010	H <sub>2</sub> C CH <sub>3</sub>
	H <sub>3</sub> C N N CH <sub>3</sub>
	O N N
	N N
	H O >
D8.011	
	N
	S S
	0,000

D8.012	H <sub>3</sub> C O O O O O O O O O O O O O O O O O O O
D8.013	O N N N H
D8.014	
D8.015	S CI
D8.016	S N F  N-N  O  N-N  O  CI

D8.017	F F O O O O O O O O O O O O O O O O O O
D8.018	
D8.019	
D8.020	
D8.021	N N N N

D8.022	OH /
	H <sub>3</sub> C N NH
	O N N
	N N
	H <sub>3</sub> C O
D8.023	0
30.020	
	$O' N = \langle NH_2 \rangle$ $NH_2 \rangle$
D8.024	s s
	N-N-N
D8.025	,
D8.025	
	O-P=O NH <sub>2</sub>
	N N N Y
	HN
	Br
D8.026	H <sub>3</sub> C NH
	O N N N
	N N
	ő

D8.027	
D8.028	
D8.029	
D8.030	OH ON NO NO NO NO NO NO NO NO NO NO NO NO
D8.031	N <sup>±</sup> O N

D8.032	O N NH <sub>2</sub> N-O O
D8.033	
D8.034	
D8.035	
D8.037	
D8.038	

D9.001	
D9.002	S N O S
D9.003	N-(-)-8-N
D9.004	SONO
D9.005	S N F  N-N  O  O  O  CI
D9.006	

D9.007	O=S=O H NH <sub>2</sub> NH <sub>2</sub> NH <sub>2</sub> F F
D9.008	O-P=O NH <sub>2</sub> HN Br
D9.010	Br O N S N S N S N S N S N S N S N S N S N
D9.011	o s o
D9.012	NH <sub>2</sub> NS OSO NH <sub>2</sub> NH <sub>2</sub>

D9.013	
D9.014	S N N OH
D9.015	CH <sub>3</sub> O S O CI CI CI

D10.002	O N Br
D10.003	
D10.004	
D10.005	
D10.007	N.N.N.N.N.N.N.N.N.N.N.N.N.N.N.N.N.N.N.
D10.008	N N H

D10.009	
D10.010	Br O O O O O O O O O O O O O O O O O O O
D10.011	
D10.012	N N N N N N N N N N N N N N N N N N N
D10.013	Br O Br
D10.014	Br Br O

D10.015	N-N N N= Br
D10.016	
D10.017	N-N N-o-
D10.018	Br O Br
D10.019	

D10.020	
D10.021	CI N N N Br
D10.022	S N N
D10.023	
D10.025	N.N.

D10.026	CI
D10.027	N N N N N N N N N N N N N N N N N N N
D10.028	
D10.029	
D10.030	
D10.031	N-N N-N

D10.032	o <sub>≈N</sub> +.o <sup>−</sup>
D10.033	0 0
	0 N-N 1 N-0
D10.034	o o_/
	$0 \longrightarrow N-N$
D10.035	CI N. O
	Br
D10.036	
	N-N-N-N-N-N-N-N-N-N-N-N-N-N-N-N-N-N-N-
D10.037	
	N N N Br
	Br Br

D10.038	
	N.N.N.N.N.N.N.N.N.N.N.N.N.N.N.N.N.N.N.
D10.039	1
	N N N
D10.040	ON NO N
D10.041	
	O N
D40.040	→
D10.042	N N N Br
D10.043	0=N+0-
	N N N
	est loto
D10.044	0 N N O -

D10.045	
D10.046	Br O N N O Br
D10.047	N-N N
D10.049	
D10.050	Br O N N O N O
D10.051	
D10.052	N-N O

D10.053	N-N O-
D10.054	Br Br
D10.055	F N N N
D10.056	
D10.057	S CI
D10.058	F S N N
D10.060	Br N-N

D10.061	
D10.062	
D10.063	O CI N
D10.065	Br O N N Br
D10.066	CI N N N N O
D10.067	Br O Br O Br

D10.068	Br I
D10.069	O_ 
D10.070	, N
:	N N N O
	O O Br
D10.071	oʻ <sup>N</sup> to_
D10.072	
D10.073	

D10.074	0,
	$\begin{array}{c c} & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & \\ & & & \\ & \\ & & \\ & & \\ & & \\ & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ &$
D10.075	
D10.076	
D10.077	
D10.078	F N N O O

D10.079	ρ <sup>-</sup>
	Br O O N O
	N N N N N N N N N N N N N N N N N N N
D40.004	Br
D10.081	
	N N
	N N
	CI
D10.082	1 0
	O Br
	O N Br
D40 000	
D10.083	
	N N N N N N N N N N N N N N N N N N N
D10.084	Br I
	O N N N N N N N N N N N N N N N N N N N
	N N Br
D10.085	
10.000	
	N. W.

D10.086	O N
	Br
	Br O
D10.087	
	-0 $N-N$ $0$
D10.088	N-0-
	S N-N
D10.089	
	Br
	Br O
D10.090	
	O N CI
D10.091	0- N-0 N-N =N
	N-N'
D10.092	
	0 N= -0
	O N

D10.093	F O O CI
D10.094	Br O O Br
D10.095	O N N Br
D10.097	
D10.098	N
D10.099	N.N.N.N.N.N.N.N.N.N.N.N.N.N.N.N.N.N.N.
D10.100	

D10.101	O-N-N N-N O-Br
D10.102	Br O O O Br
D10.103	N N N O O O
D10.105	O Br Br O Br O Br
D10.106	Br Br O Br
D10.107	
D10.108	0.N-0-

D10.109	O N N Br Br
D10.110	N N N O O O Br
D10.111	$O = N_{\downarrow}$ $O = $
D10.113	
D10.116	
D10.117	

D10.118	
D10.110	o.N.
	N-N O
	CI—O
D10.119	Br O
	Br O N N O
D10.120	
	Br O Br
D10.121	Br
	N
	N-Ñ O
	CI—O
D10.122	
	N. A. A.
D10.123	
	O N N N
D10.124	
	N-O N-V
	o <sup>-</sup>

D10.125	O <sub>≥N</sub> +.O <sup>−</sup> O
	0
D10.126	P (
	N-N-N-:0
	N O
D10.128	0
	N-N-O
D10.129	
	N N N
	<u> </u>
D10.130	
	N N N N
	N N N N
	0

D10.131	
D10.132	N N N N N N N N N N N N N N N N N N N
D10.133	O N O N O O O O O O O O O O O O O O O O
D10.134	
D10.135	Br N N N N N N N N N N N N N N N N N N N
D10.136	N.N.

D10.137	0-
	O <sup>-</sup> N
	, N O
	N-N
	Ŭ <u></u> 0
D10.138	
	Ň
D10.139	0
	CI N N N N
D10.140	
D10.140	Br 0 0
	N N N
	0
D10.141	
	\ \s-\langle
	O N
	ş
D10.142	
	N N N CI
	N <sub>N</sub> +O CI
	N N CI

D10.143	CI N N
D10.144	O N-N CI

D11.001	
D11.002	

D11.003	
	N S
	0, 0, 0
	N
	N O
	Br
D11.004	
	o(,
D11.006	
D11.007	
	, s
D11.008	Δ,0
	O N
	N N

D11.009	Me NH <sub>2</sub>
D11.010	O-N NH
D11.011	$\begin{array}{c} -O \\ O \\ N \end{array} \begin{array}{c} N \\ NH_2 \end{array}$

D12.001	
D12.002	

D12.003	CI
D12.004	O CI
D12.006	N-N-N-O
D12.009	S N N N N O O
D12.010	

D12.012	
D12.013	F N N N
D12.014	
D12.016	
D12.017	

D12.019	
D12.024	N N N O O O O O O O O O O O O O O O O O
D12.025	
D12.027	CI
D12.029	
D12.031	

D12.032	
	Br
	Br O
D12.033	
D12.034	0. N~0
	O N N
	CI
	000
D12.038	O, N
D12.040	ОН
	O N N N OH
	СІ
D12.042	0 0 N-N N-N O
	O N-N N-N O Br

D12.043	Br O N O
D12.045	N-N-N-O-O Br
D12.047	Br O
D12.050	CI N N

D13.003	NH <sub>2</sub> O H
D13.004	
D13.005	CI NH <sub>2</sub> O
D13.006	NH <sub>2</sub> O
D13.007	CI NOO

D14.001	H O OH
---------	--------

D14.002	
D14.003	H O OH
D14.004	CI N O CI CI
D14.005	H OH
D14.006	

79. (new) A method of inhibiting an activity of at least one enzyme selected from dipeptidyl peptidase IV and analogous enzymes in a subject in need thereof, wherein the method comprises administering to the subject at least one of a composition of claim 77 and an active ingredient thereof, alone or in combination with one or more inhibitors of alanyl aminopeptidase or analogous enzymes.

80. (new) A method of inhibiting an activity of at least one enzyme selected from dipeptidyl peptidase IV and analogous enzymes in a subject in need thereof, wherein the method comprises administering to the subject at least one of a composition of claim 78 and an active ingredient thereof, alone or in combination with one or more inhibitors of alanyl aminopeptidase or analogous enzymes.

81. (new) A method of topically influencing an activity of at least one enzyme selected from dipeptidyl peptidase IV and analogous enzymes in a subject in need thereof, wherein the method comprises topically administering to the subject at least one of a composition of claim 77 and an active ingredient thereof.

alone or in combination with one or more inhibitors of alanyl aminopeptidase or analogous enzymes.

82. (new) A method of topically influencing an activity of at least one enzyme selected from dipeptidyl peptidase IV and analogous enzymes in a subject in need thereof, wherein the method comprises topically administering to the subject at least one of a composition of claim 78 and an active ingredient thereof, alone or in combination with one or more inhibitors of alanyl aminopeptidase or analogous enzymes.

83. (new) A method of preventing or treating at least one condition selected from multiple sclerosis, Morbus Crohn, Colitis ulcerosa and other autoimmune diseases; inflammatory diseases; allergic asthma bronchiale and other allergic diseases; rejection of transplanted tissues and cells; skin and mucosa diseases such as psoriasis and acne; dermatological diseases associated with a hyperproliferation and changed differentiation states of fibroblasts, preferably of benign fibrosing and sclerosing skin diseases and malign fibroblastar hyperproliferation states; acute neuronal diseases, in particular ischemia-caused cerebral damage after an ischemic or hemorrhagic stroke, cranio-cerebral trauma, cardiac arrest, myocardial infarction or as a consequence of heart surgery; chronic neuronal diseases, in particular Morbus Alzheimer, Pick's disease. Progressive Supranuclear Palsy, corticobasal degeneration, frontotemporal dementia, Morbus Parkinson, in particular Morbus Parkinson coupled to chromosome 17, Morbus Huntington, prion-caused diseases and amyotrophic lateral sclerosis; chronic obstructive pulmonal disease (COPD); prostata carcinoma and other tumors as well as metastases; Heavy Acute Respiratory Syndrome (SARS); and sepsis and sepsis-like conditions in a subject in need thereof, wherein the method comprises administering to the subject at least one of a composition of claim 77 and an active ingredient thereof in an amount sufficient for preventing or treating the at least one condition.

84. (new) A method of preventing or treating at least one condition selected from multiple sclerosis, Morbus Crohn, Colitis ulcerosa and other autoimmune diseases; inflammatory diseases; allergic asthma bronchiale and other allergic diseases; rejection of transplanted tissues and cells; skin and mucosa diseases such as psoriasis and acne; dermatological diseases associated with a hyperproliferation and changed differentiation states of fibroblasts, preferably of benign fibrosing and sclerosing skin diseases and malign fibroblastar hyperproliferation states; acute neuronal diseases, in particular ischemia-caused cerebral damage after an ischemic or hemorrhagic stroke, cranio-cerebral trauma, cardiac arrest, myocardial infarction or as a consequence of heart surgery; chronic neuronal diseases, in particular Morbus Alzheimer, Pick's disease. Progressive Supranuclear Palsy, corticobasal degeneration, frontotemporal dementia, Morbus Parkinson, in particular Morbus Parkinson coupled to chromosome 17, Morbus Huntington, prion-caused diseases and amyotrophic lateral sclerosis; chronic obstructive pulmonal disease (COPD);



prostata carcinoma and other tumors as well as metastases; Heavy Acute Respiratory Syndrome (SARS); and sepsis and sepsis-like conditions in a subject in need thereof, wherein the method comprises administering to the subject at least one of a composition of claim 78 and an active ingredient thereof in an amount sufficient for preventing or treating the at least one condition.

85. (new) A method of preventing or treating at least one condition selected from atherosclerosis, arterial inflammation, vasculitides, reperfusion syndrome and stent restenosis, for example after a percutaneous transluminal angioplasty, in a subject in need thereof, wherein the method comprises administering to the subject at least one of a composition of claim 77 and an active ingredient thereof in an amount sufficient for preventing or treating the at least one condition.

86. (new) The method of claim 85, wherein the method comprises administering the at least one of a composition and an active ingredient thereof by using a stent which is coated with the at least one of a composition and an active ingredient thereof.

87. (new) A stent which is coated with at least one of a composition of claim 77 and an active ingredient thereof.

88. (new) A method of preventing or treating at least one condition selected from atherosclerosis, arterial inflammation, vasculitides, reperfusion syndrome



and stent restenosis, for example after a percutaneous transluminal angioplasty, in a subject in need thereof, wherein the method comprises administering to the subject at least one of a composition of claim 78 and an active ingredient thereof in an amount sufficient for preventing or treating the at least one condition.

89. (new) The method of claim 88, wherein the method comprises administering the at least one of a composition and an active ingredient thereof by using a stent which is coated with the at least one of a composition and an active ingredient thereof.

90. (new) A stent which is coated with at least one of a composition of claim 78 and an active ingredient thereof.

91. (new) A method of preventing or treating an inflammation reaction at, or caused by, a medical device implanted into an organism, wherein the method comprises administering to the organism at least one of a composition of claim 77 and an active ingredient thereof in an amount sufficient for preventing or treating the inflammation reaction.

92. (new) The method of claim 91, wherein the method comprises administering the at least one of a composition and an active ingredient thereof at least one of as a coating or layer on the medical device and incorporated in the medical device.